Q1 2024 13F Holders as of 31 Mar 2024
-
Type / Class
-
Equity / Class A common stock
-
Shares outstanding
-
4,195,190
-
Total 13F shares
-
326,146
-
Share change
-
+110,029
-
Total reported value
-
$1,236,215
-
Put/Call ratio
-
128%
-
Price per share
-
$3.79
-
Number of holders
-
15
-
Value change
-
+$436,469
-
Number of buys
-
6
-
Number of sells
-
5
Institutional Holders of Enlivex Therapeutics Ltd. - Class A common stock (ENLV) as of Q1 2024
As of 31 Mar 2024,
Enlivex Therapeutics Ltd. - Class A common stock (ENLV) was held by
15 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
326,146 shares.
The largest 10 holders included
MORGAN STANLEY, RENAISSANCE TECHNOLOGIES LLC, SUSQUEHANNA INTERNATIONAL GROUP, LLP, CITADEL ADVISORS LLC, SIMPLEX TRADING, LLC, GEODE CAPITAL MANAGEMENT, LLC, WELLS FARGO & COMPANY/MN, GROUP ONE TRADING, L.P., JPMORGAN CHASE & CO, and UBS Group AG.
This page lists
15
institutional shareholders reporting positions in this security
for the Q1 2024 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.